Strides Arcolab gets Health Canada nod for Tazocin generic

New Delhi, Mar 12 (UNI) Drugmaker Strides Arcolab Ltd today said it has receieved its second ANDS approval from Health Canada for Tazo Pip Sterile Injection.

The drug is licensed to an undisclosed partner in Canada and Strides excpects to launch the product immediately, a company statement said.

Pip Taz is amongst the various sterile submissions the Company has submitted with Health Canada.

''We are delighted with the approval of Tazo Pip which is an extremely important sterile product and we are further delighted that we are amongst the first wave of approvals for this significant product,'' Vice Chairman and Group CEO (Strides Arcolab) Arun Kumar said.

Tazo Pip is a generic version of Tazocin registered trade mark of Wyeth.

Market for Pip Taz in Canada is approximately 20 million dollars and has global sales of over 500 million dollars.

UNI BJR PBB HS1358